Glenmark Pharmaceuticals Limited reported earnings results for the full year ended March 31, 2024. For the full year, the company reported sales was INR 116,354.56 million compared to INR 114,319.38 million a year ago. Revenue was INR 126,530.91 million compared to INR 118,721.36 million a year ago.

Net loss was INR 15,016.68 million compared to net income of INR 2,972.45 million a year ago. Basic loss per share from continuing operations was INR 67.3 compared to INR 6.01 a year ago. Diluted loss per share from continuing operations was INR 67.3 compared to INR 6.01 a year ago.

Basic loss per share was INR 53.22 compared to basic earnings per share of INR 10.53 a year ago. Diluted loss per share was INR 53.22 compared to diluted earnings per share of INR 10.53 a year ago.